Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 7/20 | 0.54 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.54 |
| ▸ | CTSD | P07339 | 1/20 | 0.52 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.52 |
| ▸ | CTSK | P43235 | 3/20 | 0.48 |
| ▸ | REN | P00797 | 1/20 | 0.46 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 2/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21458035 | 1.00 | CAPN1 (0.54) | CAPN1PSMB1CTSDCAPN2CTSK | |
| SCHEMBL21457975 | 0.94 | CAPN1 (0.56) | CAPN1PSMB1CAPN2CTSKCTSL | |
| SCHEMBL4400925 | 0.94 | CAPN1 (0.56) | CAPN1PSMB1CAPN2CTSKCTSL | |
| SCHEMBL4391579 | 0.93 | CAPN1 (0.58) | CAPN1PSMB1CAPN2CTSKCTSL | |
| SCHEMBL21458045 | 0.93 | CAPN1 (0.58) | CAPN1PSMB1CAPN2CTSKCTSL | |
| SCHEMBL20834987 | 0.91 | CAPN1 (0.58) | CAPN1PSMB1CAPN2CTSKCTSL | |
| SCHEMBL3840049 | 0.91 | CAPN1 (0.58) | CAPN1PSMB1CAPN2CTSKCTSL | |
| SCHEMBL21457976 | 0.91 | CAPN1 (0.58) | CAPN1PSMB1CAPN2CTSKCTSL | |
| SCHEMBL4392057 | 0.85 | CAPN1 (0.54) | CAPN1PSMB1CTSKRENCTSL | |
| SCHEMBL28028195 | 0.85 | CTSD (0.50) | CAPN1PSMB1CTSDCAPN2CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11844776-B2 | Composition for treatment and/or prevention of peripheral nerve disorder | OSAKA CITY UNIVERSITY (JP) | 2023-12-19 | — | — | US | disclosed |
| EP-3466421-B1 | COMPOSITION FOR THE TREATMENT OF PERIPHERAL NERVE DISORDERS | UNIV OSAKA CITY (JP) | 2022-11-30 | — | — | EP | disclosed |
| US-20190314320-A1 | COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PERIPHERAL NERVE DISORDER | OSAKA CITY UNIVERSITY (JP) | 2019-10-17 | — | — | US | disclosed |
| EP-3466421-A1 | COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PERIPHERAL NERVE DISORDER | Osaka City University (JP) | 2019-04-10 | — | — | EP | disclosed |
| EP-2647386-B1 | LISSENCEPHALY THERAPEUTIC AGENT | UNIV OSAKA CITY (JP) | 2018-09-05 | — | — | EP | disclosed |
| US-9539298-B2 | Lissencephaly therapeutic agent | OSAKA CITY UNIVERSITY (JP) | 2017-01-10 | — | — | US | disclosed |
| US-20160250276-A1 | LISSENCEPHALY THERAPEUTIC AGENT | OSAKA CITY UNIVERSITY (JP) | 2016-09-01 | — | — | US | disclosed |
| US-9371359-B2 | Lissencephaly therapeutic agent | OSAKA CITY UNIVERSITY (JP) | 2016-06-21 | — | — | US | disclosed |
| EP-2647386-A1 | LISSENCEPHALY THERAPEUTIC AGENT | Osaka City University (JP) | 2013-10-09 | — | — | EP | disclosed |
| US-20130244945-A1 | LISSENCEPHALY THERAPEUTIC AGENT | OSAKA CITY UNIVERSITY | 2013-09-19 | — | — | US | disclosed |
| US-7491705-B2 | Alpha-ketoamide derivative, and production method and use thereof | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2009-02-17 | — | — | US | disclosed |
| US-20070004643-A1 | Alpha-ketoamide derivative, and production method and use thereof | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2007-01-04 | — | — | US | disclosed |
| EP-1692098-A1 | ALPHA-KETOAMIDE DERIVATIVE, AND PRODUCTION METHOD AND USE THEREOF | Senju Pharmaceutical Co., Ltd. (JP) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005056519-A1 | ALPHA-KETOAMIDE DERIVATIVE, AND PRODUCTION METHOD AND USE THEREOF | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130244945-A1 | LISSENCEPHALY THERAPEUTIC AGENT | ASPH, DCX, ERH | CAPN1 2767/4885PSMB1 2026/4885CTSD 3664/4885 |
| US-20190314320-A1 | COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PERIPHERAL NERVE DISORDER | PMP22, PRPH, NGF | CAPN1 4158/4885PSMB1 2040/4885CTSD 3733/4885 |
| US-20070004643-A1 | Alpha-ketoamide derivative, and production method and use thereof | CAPN1, CAPN2, CAPNS1 | CAPN1 1/4885PSMB1 8/4885CTSD 331/4885 |
| US-20160250276-A1 | LISSENCEPHALY THERAPEUTIC AGENT | ASPH, DCX, P4HA1 | CAPN1 2695/4885PSMB1 1971/4885CTSD 3749/4885 |
| US-11844776-B2 | Composition for treatment and/or prevention of peripheral nerve disorder | PMP22, PRPH, NGF | CAPN1 4158/4885PSMB1 2040/4885CTSD 3733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.